Back to previous page

Independent report

The Biomedical Catalyst: an evaluation report

This report contains the findings of an independent review and impact assessment of the Biomedical Catalyst programme.

From:
Innovate UK
Published:
Last updated:
- see all updates

Documents

Biomedical Catalyst impact evaluation: final report (PDF)

, 818 KB

If you cannot open or read this document, you can ask for a different format.

Request a different format

Email web@ukri.org, telling us:

  • the name of the document
  • what format you need
  • any assistive technology you use (such as type of screen reader).

Find out about our approach to the accessibility of our website.

Biomedical Catalyst impact evaluation: annexes (PDF)

, 4 MB

If you cannot open or read this document, you can ask for a different format.

Request a different format

Email web@ukri.org, telling us:

  • the name of the document
  • what format you need
  • any assistive technology you use (such as type of screen reader).

Find out about our approach to the accessibility of our website.

Details

Innovate UK and the Medical Research Council (MRC) commissioned Ipsos Mori to carry out a two-stage review of the Biomedical Catalyst.

This report provides the results of the first stage of the evaluation process.

Some of the report’s main findings include:

  • projects receiving Biomedical Catalyst funding progress faster than they would otherwise have done
  • Biomedical Catalyst funding encourages companies to switch from low risk or low return projects to those with high risk or higher return
  • stakeholders agreed that the Biomedical Catalyst aligns with Innovate UK and MRC strategies
  • applicants thought the application process was straightforward and encouraged high-quality submissions
  • marketing to the biopharma and academic communities was successful
  • the Biomedical Catalyst should seek to increase outreach to the medtech community and emerging sectors such as digital health

Future evaluation of the Biomedical Catalyst

The second phase of the evaluation will begin in 2017 and will build upon this baseline study. It will report on the outcomes and impacts since the launch of the Biomedical Catalyst.

About the Biomedical Catalyst

The Biomedical Catalyst is a partnership between Innovate UK and MRC. It supports the most innovative life sciences opportunities. Its aims are to de-risk innovative science and commercialise the ideas that come from academia and industry. It helps UK SMEs develop into competitive and sustainable businesses.

Updates

  • 6 January 2023
    Final report document updated to most recent evaluation in 2019.

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.